Hemptown buys FDA-approved plant with $6 mil/year existing revenue

I once consulted with a veteran CEO (potash, lithium, tech, gold) who told me, “Before I take a company public, I’ve got 60 press releases written in my head”.

Since the man had created over $1 billion in enterprise value, I wasn’t going to argue with his roll-out template.

His idea: you don’t take a company public, then scramble around for meaningful ways to add value/de-risk it – that plan is already in place.  Letters of Intent (LOIs) ready to sign, land acquisitions waiting to close, FCC approvals pending.

Hemptown USA – a CBD/CBG company – has an entirely different strategy.

The company isn’t yet public (we are expecting an IPO in Q4, 2019), but they have already raised $23 million and made a number of strategic acquisitions.

By the time the first share is traded, Hemptown will already be a mature company.

On July 10, 2019 Hemptown announced that it has acquired “all or substantially all” of the FDA licensed nutraceutical business of the Kirkman Group based in Lake Oswego, Oregon.

The transaction includes all of the management team, production equipment, formulations, proprietary IP, current sales channels, and fulfillment centers.

Kirkman’s Key Features:

  • Fully operational FDA licensed, cGMP 25,000 sq. ft. nutraceutical manufacturing facility, with over 1,200 SOPs.
  • 70 years of supplying world class formulations for children with autism and special needs
  • Existing $6 million annual revenue
  • Revenues are expanding.
  • Former owner and Chairman David Humphreys, a board member on the American Academy of Cannabinoid Medicine (AACM), will assist in liaising with the community of doctors who focus on cannabinoid medicine.
  • Facility is comprised of state-of-the-art formulations and equipment to facilitate precision dosage CBD & CBG liquid fill tinctures, creams and topicals, gel caps, and gums/edibles.
  • Key Kirkland management and technical team will be retained.
  • Hemptown anticipates a seamless transition to fast-track CBD/CBG product formulations into wholesale, retail and on-line markets.

This acquisition gives Hemptown immediate entry into the Consumer Packaged Goods space.

To understand why that is critical, we have to crank back two months to Hemptown announcing the completion of a $23 million financing, led by Canaccord Genuity.

Hemptown is growing 1,500 acres of high-grade “feminized hemp” in Oregon, on the northern tip of the famous weed-growers Emerald Triangle.

Feminised hemp comes from genetically altered seeds.  Typically, they produce more medically active substances such CBD and CGB, than a male plant.

In other words, the company has biomass, which it could sell for a modest profit (“rich farmer” is an oxymoron).But to generate serious profits, Hemptown plans to distil the hemp into full-spectrum CBD and “CBG crude” (more on CBG in a minute).

Hemptown could take some of that $23 million raised and build an FDA licensed, cGMP nutraceutical manufacturing facility, but to set up protocols, recruit scientists, test the lab equipment and get government approvals could take years.

In this frontier market, time is market-share.

Hemptown wants to harvest the hemp, process it, and get its product on the shelves asap.

Hemptown believes the nutraceutical industry standards for producing finished goods will soon be a requirement for all products being sold in the marketplace.

Hemptown’s objective is to be one of the largest producers of CBG in North America.

CBG is the precursor to all cannabinoids and is commonly known as “The Mother of All Cannabinoids.”

Hemptown is growing over 500 acres focused exclusively on these rare genetics in an effort to become a dominate North American supplier of CBG by the end of 2019.

According to a well-researched article by Jacqueline Havelka on Leafly.com, “CBG is a powerful vasodilator that has neuroprotective effects” while also showing “great promise as a cancer fighter.”

Hemptown USA is monetizing the present (CBD) while looking to the future (CBG) for enhanced revenues.

Preparing nutraceutical formulations for autistic children is not a culinary process.

It’s a scientific one.

Kirkman’s “Ultra Tested” protocols screen for more than 950 environmental contaminants while finished products will be tested for 24 heavy metals, bacteria, yeast, mold and common allergens.

The wellness industry is populated by a galaxy of doctors, dieticians and health experts.  In this world, standardisation of product and precision of dosage is paramount.

“Ultra Tested is the highest standard of purity testing in the nutritional supplement industry.  Hemptown will be one of the first companies to offer product liability insurance on all future Consumer Packaged Goods produced at the facility.”

“The team at Kirkman’s is delighted to now be part of the Hemptown USA group,” stated Humphrey, “Coupled with Hemptown’s deep expertise in farming and extracting novel cannabinoids, the company will be able to add to Kirkman’s product offerings.”

The Skinny on Hemptown USA:

  • 1st year yield of 110,000 lbs of feminized hemp biomass.
  • Projected gross margin greater than 77% on average from 2018’s harvest.
  • Purchase of 1 million rare CBG seeds for the 2019 growing season.
  • Coveted strain profiles containing 15% – 20% full spectrum CBD, CBG and other cannabinoids and terpenes.
  • Presently growing 1,500 acres in Oregon, Kentucky and Colorado.
  • Capability to double the acreage in 2020 and each year after.
  • An R&D plan for mass production of novel cannabinoid strains (CBC, CBDV and CBGV) in 2020, 2021 and 2022.
  • Now owns FDA approved manufacturing plant with $6 million annual revenue.

Equity.Guru’s Chris Parry recently spoke with Hemptown co-founder, director and president, Michael Townsend, to lift up the hood on the company, its revenue run and its highly anticipated IPO expected in Q4 2019.

This swaggering (eye candy) new video gives an alternative  overview:

“The Kirkman Group is a key strategic acquisition for Hemptown,” stated Rod Wolterman, Chairman and Founder of Hemptown USA, “Being fully operational and FDA licensed accelerates Hemptown’s vertical integrations plans.”

Pre-IPO.

Post-revenue.

This company has a plan.

Full Disclosure: Hemptown USA is an Equity Guru marketing client.

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Leave a Reply

3 Comments on "Hemptown buys FDA-approved plant with $6 mil/year existing revenue"

Notify of
avatar
Sort by:   newest | oldest | most voted
Bri
Guest

How can we buy the pre IPO shares?

Raymond
Guest

Hello, how do I invest in Hemptown USA while it is still a private company?
I like your style and commitment.

Cheers
Raymond ( from Queensland, Australia.)